Information Provided By: 
Fly News Breaks for June 30, 2015
JUNO, CELG
Jun 30, 2015 | 07:14 EDT
UBS said Celgene's (CELG) partnership deal with Juno Therapeutics (JUNO) is probably good, though it will take time for the fundamentals to play out. The firm likes Celgene's investment in innovative programs and expects its multiple to expand as investors look toward its pipeline. UBS reiterated its Buy rating and $130 price target on Celgene shares.
News For CELG;JUNO From the Last 2 Days
There are no results for your query CELG;JUNO
